Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece

Clinical Drug Investigation

Volumn 37, Issue 9, 2017, Pages 833-844

  Gourzoulidis, George ^a   Kourlaba, Georgia ^b   Kakisis, John ^b   Matsagkas, Mitiadis ^c   Giannakoulas, George ^d   Gourgoulianis, Konstantinos I ^e   Vassilakopoulos, Theodoros ^b   Maniadakis, Nikos ^a  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; ENOXAPARIN; RIVAROXABAN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ARTICLE; BLEEDING; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; GREECE; HUMAN; LUNG EMBOLISM; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TREATMENT DURATION; AGED; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; VEIN THROMBOSIS;

AGED; ANTICOAGULANTS; COST-BENEFIT ANALYSIS; ENOXAPARIN; FIBRINOLYTIC AGENTS; GREECE; HUMANS; MIDDLE AGED; PULMONARY EMBOLISM; QUALITY-ADJUSTED LIFE YEARS; RIVAROXABAN; VENOUS THROMBOSIS;

EID: 85020695360     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-017-0540-1     Document Type: Article

References (59)

1. Moheimani F, Jackson DE. Venous thromboembolism: classification, risk factors, diagnosis, and management. ISRN Hematol. 2011;2011:124610.
2. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. JTH. 2005;3(8):1611–7.
3. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. New Engl J Med. 2004;350(22):2257–64.
4. Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ. 2011;14(1):65–74.
5. Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy. 2009;29(8):943–53.
6. National Institute for Health and Care Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical guidelines, CG144. http://www.nice.org.uk/guidance/CG144. Available from: Cited 18 Feb 2016.
7. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35(43):3033–69, 69a–69k.
8. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.
9. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160S–98S.
10. Key NS, Kasthuri RS. Current treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010;30(3):372–5.
11. Garcia DA. Current therapeutic strategies and future perspectives for the treatment of venous thromboembolism. Curr Pharm Des. 2010;16(31):3475–7.
12. van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968–75.
13. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30(3):376–81.
14. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharm Therap. 2005;78(4):412–21.
15. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med. 2010;363(26):2499–510.
16. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New Engl J Med. 2012;366(14):1287–97.
17. van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AW. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin. 2014;30(5):829–37.
18. Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. J Med Econ. 2014;17(10):691–5.
19. Bamber L, Muston D, McLeod E, Guillermin A, Lowin J, Patel R. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thromb J. 2015;13:20.
20. Kourlaba G, Rapti V, Alexopoulos A, Relakis J, Koumakis G, Chatzikou M, et al. Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: an economic evaluation study. BMC Health Serv Res. 2015;15:307.
21. Maniadakis N, Kaitelidou D, Siskou O, Spinthouri M, Liaropoulos L, Fragoulakis B, et al. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece. Hellenic J Cardiol. 2005;46(3):212–21.
22. Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv Res. 2014;14:419.
23. Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, et al. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ. 2014;17(1):52–64.
24. de Jong LA, Dvortsin E, Janssen KJ, Postma MJ. Cost-effectiveness analysis for apixaban in the acute treatment and prevention of venous thromboembolism in the Netherlands. Clin Therap 2017;39(2):288–302.e4.
25. Seaman CD, Smith KJ, Ragni MV. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective. Thromb Res. 2013;132(6):647–51.
26. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397–409.
27. Sun X, Faunce T. Decision-analytical modelling in health-care economic evaluations. Eur J Health Econ. 2008;9(4):313–23.
28. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health J Int Soc Pharmacoecon Outcome Res. 2013;16(2):e1–5.
29. National Institute for Health and Care Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical guidelines, CG144. 2015. Available from: https://www.nice.org.uk/guidance/CG144. Cited 20 Apr 2017.
30. Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2008;177(10):1122–7.
31. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316(7133):736–41.
32. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inf Assoc. 1997;4(1):49–56.
33. Linkins L, O’Donnell M, Julian JA, Kearon C. Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. JTH. 2010;8(10):2201–7.
34. Locadia M, Bossuyt PM, Stalmeier PF, Sprangers MA, van Dongen CJ, Middeldorp S, et al. Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences. Thromb Haemost. 2004;92(6):1336–41.
35. Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med. 2001;111(2):130–9.
36. Mayer E, Jenkins D, Lindner J, D’Armini A, Kloek J, Meyns B, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thoracic Cardiovasc Surg. 2011;141(3):702–10.
37. Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J, et al. The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J. 2008;32(6):1513–9.
38. Miniati M, Monti S, Bottai M, Scoscia E, Bauleo C, Tonelli L, et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Med (Baltimore). 2006;85(5):253–62.
39. Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82(4):423–8.
40. Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez R. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making. 2010;30(3):341–54.
41. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199–205.
42. Greek Ministry of Health. Drug price bulletin 2017. Available from: http://www.moh.gov.gr/articles/times-farmakwn/deltia-timwn. Cited 20 Feb 2017.
43. Greek Ministry of Health. Diagnostic related groups Athens. Available from: http://kenicd.ehealthnet.gr/%CE%A0%CF%81%CE%BF%CE%B2%CE%BF%CE%BB%CE%B7.aspx. Cited 12 Jun 2017.
44. National Organisation for HealthcareServices Provision. Official web site of EOPYY, 2017. Available from: http://www.eopyy.gov.gr/Home/StartPage?a_HomePage=Index. Cited 22 Jan 2017.
45. Maniadakis N, Kourlaba G, Cokkinos DV, Angeli A, Kyriopoulos J. The economic burden of atherothrombosis in Greece: results from the THESIS study. Eur J Health Econ. 2013;14(4):655–65.
46. Hellenic Statistical Authority (EL. STAT.). Inflation rates. Available from: http://www.statistics.gr/. Cited 12 Jun 2017.
47. WHO. Choosing interventions that are Cost Effective (WHO-CHOICE): Cost-effectiveness thresholds 2015. Available from: http://www.who.int/choice/costs/CER_thresholds/en/index.html. Cited 28 Apr 2017.
48. International Monetary Fund. World Economic Outlook Database. Available from: http://www.imf.org/external/pubs/ft/weo/2017/01/weodata/index.aspx. Cited 28 Apr 2017.
49. Coleman CI, Limone BL, Bookhart BK, Mody SH, Nutescu EA. Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism. Thromb Res. 2014;133(5):743–9.
50. Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost. 2010;104(4):760–70.
51. Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective. J Med Econ. 2011;14(6):824–34.
52. Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer’s perspective. Pharmacoeconomics. 2012;30(2):87–101.
53. McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F, et al. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: a Canadian analysis using the Ontario Ministry of Health Perspective. J Med Econ. 2012.
54. Ryttberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Bjorholt I. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Rev Pharmacoecon Outcome Res. 2011;11(5):601–15.
55. Kleintjens J, Li X, Simoens S, Thijs V, Goethals M, Rietzschel ER, et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics. 2013;31(10):909–18.
56. Kourlaba G, Maniadakis N, Andrikopoulos G, Vardas P. Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. Cost Eff Resour Alloc. 2014;12(1):5.
57. Lanitis T, Cotte FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. J Med Econ. 2014;17(8):587–98.
58. Mensch A, Stock S, Stollenwerk B, Muller D. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. Pharmacoeconomics. 2015;33(3):271–83.
59. Morais J, Aguiar C, McLeod E, Chatzitheofilou I, Fonseca Santos I, Pereira S. Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. Rev Port Cardiol. 2014;33(9):535–44.